v3.21.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash $ 5,069,266 $ 2,598,864
Advances on research and development contract services 76,898
Accrued interest receivable 14,367
Prepaid insurance 67,311 34,508
Other prepaid expenses and current assets 15,000 24,294
Total current assets 5,228,475 2,672,033
Total assets 5,228,475 2,672,033
Current liabilities:    
Accounts payable and accrued expenses 190,292 143,549
Accrued offering costs 10,467
Research and development contract liabilities 15,765 94,349
Total current liabilities 216,524 237,898
Commitments and contingencies
Stockholders' equity:    
Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares - 729,167 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued, issuable and outstanding - 12,402,157 shares and 11,174,737 shares at December 31, 2020 and 2019, respectively 1,240 1,117
Additional paid-in capital 31,864,479 26,021,904
Accumulated deficit (30,353,768) (27,088,886)
Total stockholders' equity 5,011,951 2,434,135
Total liabilities and stockholders' equity $ 5,228,475 $ 2,672,033

Source